Iraq is the second-largest economy in the Arab world by GDP, with oil revenues exceeding $270 billion and a population of approximately 42 million. Post-conflict reconstruction is reshaping the country's commercial landscape, creating significant opportunities in healthcare infrastructure, construction, consumer goods, and financial services. Baghdad and Erbil serve as the dual commercial hubs, each requiring distinct research strategies — Baghdad as the federal capital and Erbil as the economic gateway to the Kurdistan Regional Government (KRG) market.
The Iraqi pharmaceutical market is a complex environment shaped by the Iraqi Ministry of Health (MoH Iraq) regulatory framework, the Iraqi Pharmacovigilance Unit, and KIMADIA — the State Company for Drug and Medical Equipment Imports, Stores and Distribution — which dominates public sector pharmaceutical procurement. Private sector pharmaceutical distribution is growing steadily, and the Iraqi Medical Association plays an influential role in shaping prescribing practices. Research buyers entering the Iraqi healthcare market require partners with specific awareness of these regulatory and institutional dynamics.
Market research in Iraq demands trilingual capability across Arabic, Kurdish, and English, as well as sensitivity to the distinct commercial and political environments of the federal government territories and the KRG. Oil-funded reconstruction investment is creating new demand for market entry intelligence, consumer behaviour studies, and competitive analysis across retail, healthcare, and infrastructure sectors. The right research partner must combine rigorous global methodology with practical Iraqi execution experience.